EphB1 Inhibitors

Dasatinib is a multi-target tyrosine kinase inhibitor, known for its action on BCR-ABL and Src family kinases. Src kinase is involved in the signaling cascade of Eph receptors, and its inhibition by Dasatinib can impede downstream signaling processes, leading to reduced EphB1-mediated cellular responses. This can affect actin cytoskeleton dynamics and cell adhesion, functions in which EphB1 is a critical player.

PP2 is a selective inhibitor of Src family tyrosine kinases, which are downstream of EphB1. By inhibiting these kinases, PP2 can disrupt EphB1-mediated cell migration and adhesion, which are central to the protein's role in cellular signaling.

NVP-BHG712 is an EphB4 inhibitor that may also influence EphB1 activity by competitively inhibiting their shared ligands and thus affecting signaling pathways common to both receptors, including those involved in cell migration and organization.

SU6656 is primarily a Src family kinase inhibitor. By inhibiting Src kinases, SU6656 can interfere with the downstream signaling of EphB1, potentially reducing its ability to mediate changes in cell adhesion and the cytoskeleton.

Imatinib Mesylate is a tyrosine kinase inhibitor with activity against ABL, PDGF, and c-Kit. It may indirectly reduce EphB1 signaling by affecting the cytoskeletal arrangements and cellular adhesion through its action on these kinases.

Tyrphostin B42 is a tyrosine kinase inhibitor that targets the EGF receptor tyrosine kinase, which may indirectly influence EphB1 signaling by modulating pathways that both receptors share or crosstalk between, thereby affecting cellular adhesion and migration.

WH-4-023 is a kinase inhibitor selective for Lck and Src. Since Src kinases modulate EphB1 signaling, this compound can indirectly influence the function of EphB1 by altering the cytoskeletal dynamics and cell migration regulated by EphB1-Src interactions.

Lestaurtinib is an inhibitor of several tyrosine kinases, including JAK2, FLT3, and Trk receptors. Its inhibition of related kinases could affect EphB1 signaling indirectly by modulating the phosphorylation states of key signaling proteins involved in the same pathways as EphB1, thereby impacting cellular processes such as adhesion and migration.

Erlotinib is an EGFR inhibitor that could potentially have indirect effects on EphB1 by inhibiting shared signaling pathways or altering cellular behaviors such as migration, where EphB1 is also involved.

Saracatinib is an inhibitor of Src and Abl tyrosine kinases. Since Src kinase activity influences EphB1 receptor signaling, Saracatinib's inhibition of Src can result in downregulation of EphB1-mediated pathways involved in cellular adhesion, migration, and the architecture of the cytoskeleton.